Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
Public ClinicalTrials.gov record NCT05695417. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1B, Multicenter, Double-Masked, Randomized, Parallel Group Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI (Axitinib Implant) for Intravitreal Injection in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects with Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
Study identification
- NCT ID
- NCT05695417
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 21 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 15, 2023 (Actual)
- Primary completion
- Jan 2024 (Estimated)
- Completion
- Dec 2024 (Estimated)
- Last update posted
- Dec 8, 2023
2023 – 2024
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ocular Therapeutix Inc | Phoenix | Arizona | 85053 | — |
| Ocular Therapeutix, Inc. | Bakersfield | California | 93308 | — |
| Ocular Therapeutix, Inc. | Augusta | Georgia | 30909 | — |
| Ocular Therapeutix, Inc. | Lemont | Illinois | 60439 | — |
| Ocular Therapeutix, Inc. | Hagerstown | Maryland | 21740 | — |
| Ocular Therapeutix, Inc. | Reno | Nevada | 89502 | — |
| Ocular Therapeutiux, Inc. | Austin | Texas | 78750 | — |
| Ocular Therapeutix Inc | Bellaire | Texas | 77401 | — |
| Ocular Therapeutix, Inc | San Antonio | Texas | 78211 | — |
| Ocular Therapeutix Inc. | The Woodlands | Texas | 77384 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05695417, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 8, 2023 · Synced Nov 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05695417 live on ClinicalTrials.gov.